FYDE
4.11.2019 12:02:08 CET | Business Wire | Press release
Fyde, the new standard for Zero Trust, today announced Fyde Enterprise, a continuous, adaptive secure access solution that mitigates risk while protecting privacy and increasing performance. As digital transformation and the cloud transform the way we work and access apps, the disappearance of the traditional corporate perimeter creates new security risks and compliance challenges that break traditional solutions like VPNs. A powerful alternative to VPNs, Fyde Enterprise works on any infrastructure, any device, and with any application on a corporate network. Distributed businesses can now modernize remote access, enforce global security and access policies, and achieve seamless connectivity without compromising productivity.
Fyde, a first-time participant at Web Summit, is a featured startup and will be speaking on Centre Stage at the Breakout startups on November 4 at 5:00 pm and November 6 at 9:15 am. Fyde is also an exhibitor in the Beta Startup Programme on Tuesday, November 5.
Zero Trust for the Modern Enterprise
The Zero Trust paradigm assumes that all access is conditional and the network is always untrusted. Every interaction with the corporate network or cloud infrastructure must be granted contextual and conditional access based on continuous evaluation of device attributes (such as critical updates, security configuration and geographic location) and user identity (such as enforcing MFA or re-authentication) to ensure the highest levels of security.
Security teams must adapt to new requirements for the cloud, employee mobile devices, and evolving access dynamics associated with contractors, partners and remote employees. Fyde’s Zero Trust approach to secure access is driven by identity-aware access control and device-trust based security policies. Fyde enables secure, reliable and fast access to authorized apps and workloads on corporate networks and cloud infrastructure from any device, network, and location. Fyde also protects user identities from account takeover attacks.
“CISOs are frustrated by the failure of their traditional secure access solutions to deliver essential visibility and control over access to corporate resources, as well as to block emerging threats,” said Sinan Eren, Fyde CEO. “Fyde is built to address the security challenges created by the evolving threat landscape, while protecting employee privacy, boosting productivity, and ensuring compliance.”
Fyde Enterprise: The Onramp to Zero Trust
Fyde Enterprise is easy to deploy, monitor and manage. Security and IAM teams can sync with their user directory for seamless onboarding and deprovisioning of users and devices, monitor and log access requests and sessions via the Fyde Enterprise management console. Fyde Enterprise includes features for today’s complex IT environments, enabling security teams to deliver:
Zero Trust on any infrastructure or platform
- Grant minimal privileged access to authorized apps without exposing the network
- Work on Mobile or Desktop
- Deploy on-premises or in hybrid or public cloud
- Continuously verify users and devices
Global Security and Access Policies
- Create robust access policies and gain visibility into who has access, to what and from where
- Assign role-based and attribute-based policies
Upgraded performance and privacy
- Eliminate latency via local inspection
- Offer self-service remediation
- Reduce IT Costs
- Secure the data plane: Fyde does not have visibility into data.
- Protect employee privacy. No personal data is shared with the company.
Pricing and availability
Fyde Enterprise is available today. Fyde is sold as an annual subscription with pricing starting at $10 per user per month. Enterprise bundles are available. To try Fyde today, visit Fyde.com/sign-up
About Fyde
Fyde is the new standard for Zero Trust secure access. An increasingly decentralized world is driving digital transformation and challenging the status quo. Fyde helps organizations mitigate risks while adapting to the new nature of work and IT, powering their journey to the Zero Trust Architecture. Our innovative approach is driven by patented technology that enables secure, reliable and fast access to any on-premises, cloud or hybrid app or workload. Fyde eliminates security risks associated with traditional VPN access, while protecting user identities from account takeover attacks. To learn more about Fyde, visit Fyde.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005177/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
